
FNCHQ
Healthcare · Biotechnology · $16.6M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 8, 2024 | Time not confirmed | — | -3.01 | — |
| May 9, 2024 | Time not confirmed | — | -2.41 | — |
| Mar 28, 2024 | Time not confirmed | — | -1.89 | — |
| Nov 9, 2023 | Time not confirmed | — | -1.51 | — |
| Aug 10, 2023 | Before the open | -4.50 | -3.83 | +14.9% |
| May 10, 2023 | Before the open | -2.70 | -10.73 | -297.4% |
| Mar 24, 2023 | Time not confirmed | -10.20 | -16.75 | -64.2% |
| Nov 10, 2022 | Before the open | -13.50 | -13.23 | +2.0% |
| Aug 11, 2022 | Before the open | -12.45 | -13.74 | -10.4% |
| May 16, 2022 | Time not confirmed | — | -15.51 | — |
| Mar 31, 2022 | After the close | -9.60 | -12.00 | -25.0% |
| Nov 10, 2021 | Before the open | -12.60 | -6.30 | +50.0% |
| Aug 10, 2021 | Before the open | -7.80 | -9.60 |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including…
| -23.1% |
| May 13, 2021 | Before the open | -7.20 | -18.60 | -158.3% |